Martin Shkreli Publishes Bull Case for Photonic Computing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 06 2026
0mins
Should l Buy NVDA?
Source: Benzinga
- Photonic Computing Potential: Martin Shkreli argues in his Substack essay that photonic computing can perform matrix operations using light instead of electrical signals, potentially reducing computation time from cubic to near-linear, which could have significant market implications if realized.
- Investment and Advisory Role: Shkreli has been a strategic advisor to Q/C Technologies Inc. since December, emphasizing his confidence in photonic computing, which may attract more investor interest in this emerging field.
- Market Reaction and Risks: While Shkreli's insights could lead to a reevaluation of market predictions for companies like Nvidia, skepticism remains regarding the near-term threat of photonic computing, indicating cautious investor sentiment towards this technology.
- Company Financials: QCLS is facing financial challenges with a trailing twelve-month net loss of approximately $23.4 million and minimal revenue, and although its stock rose 27% on Thursday, it remains significantly below its 52-week high, reflecting uncertainty about its future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVDA
Wall Street analysts forecast NVDA stock price to rise
41 Analyst Rating
39 Buy
1 Hold
1 Sell
Strong Buy
Current: 165.170
Low
200.00
Averages
264.97
High
352.00
Current: 165.170
Low
200.00
Averages
264.97
High
352.00
About NVDA
NVIDIA Corporation is an artificial intelligence (AI) infrastructure company. The Company is engaged in accelerated computing to help solve the challenging computational problems. Its segments include Compute & Networking and Graphics. The Compute & Networking segment includes its Data Center accelerated computing and networking platforms and AI solutions and software, and automotive platforms and autonomous and electric vehicle solutions, including software. The Graphics segment includes GeForce GPUs for gaming and personal computers (PCs), and Quadro/NVIDIA RTX GPUs for enterprise workstation graphics. Its technology stack includes the foundational NVIDIA CUDA development platform that runs on all NVIDIA GPUs, as well as hundreds of domain-specific software libraries, frameworks, algorithms, software development kits (SDKs), and application programming interfaces (APIs). Its platforms address four markets, which include Data Center, Gaming, Professional Visualization, and Automotive.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nvidia Reports 65% Revenue Growth in Fiscal 2026
- Significant Revenue Growth: Nvidia reported a revenue of $215.9 billion for fiscal 2026, reflecting a 65% year-over-year increase, despite a 10.2% decline in stock price so far in 2026, indicating market concerns about the sustainability of AI infrastructure spending.
- Robust AI Demand Outlook: CEO Jensen Huang announced at the GTC AI Conference that demand for AI systems is projected to reach at least $1 trillion in 2026 and 2027, a substantial increase from the previous estimate of $500 billion, highlighting the long-term trend in AI infrastructure development.
- Diversified Customer Base: Nvidia's business is composed of 60% from hyperscalers and 40% from enterprises, sovereign AI projects, startups, and emerging applications, ensuring that the company is not overly reliant on any single industry, thereby mitigating market risks.
- Continuous Product Innovation: Nvidia is actively launching new products, with ongoing deployments of Hopper systems and ramping up Blackwell systems, while future platforms like Rubin and Feynman are already in development, enhancing the company's competitive edge in the market.
See More
Harbor Capital's Strategic Buy and Sell Moves in Q1 2026
- New Stock Additions: In Q1 2026, Harbor Capital added three stocks, with Merck & Co (MRK) being the largest at 2,020,767 shares, accounting for 0.86% of the portfolio and valued at $222.83 million, indicating confidence in the pharmaceutical sector.
- Key Position Increases: The fund increased its stake in Amphenol Corp (APH) by 818,193 shares, representing a significant 58.39% increase, bringing total holdings to 2,219,459 shares with an overall investment value of $319.78 million, reflecting optimism about its growth potential.
- Complete Exits: Harbor Capital fully exited four holdings in Q1, including Nike (NKE) and Boston Scientific (BSX), impacting the portfolio by -0.74% and -0.45% respectively, indicating a cautious outlook on these companies.
- Position Reductions: The fund reduced stakes in 34 stocks, notably cutting NVIDIA (NVDA) by 3,792,310 shares, resulting in a 20.42% decrease and a -2.61% portfolio impact, showcasing a strategic response to market volatility.
See More
Nvidia Invests Over $18B to Propel AI Ecosystem
- Total Strategic Investments: Nvidia has invested at least $18 billion in publicly traded companies over the past six months, underscoring its ongoing expansion and dominance in the AI sector.
- Partnership with Marvell: The latest $2 billion investment in Marvell Technology aims to connect Marvell to Nvidia's AI factory and AI-RAN ecosystem through NVLink Fusion, further solidifying their strategic partnership.
- Diverse Investment Strategy: Earlier this month, Nvidia invested $2 billion in Dutch AI infrastructure provider Nebius, planning to deploy over 5 gigawatts of Nvidia systems by the end of 2030, showcasing its ambition in global AI infrastructure development.
- Historic Collaboration with Intel: Nvidia's $5 billion share purchase from Intel at the end of 2025 aims to tightly integrate Nvidia's AI computing platform with Intel's CPUs, laying the groundwork for the next era of computing.
See More
Goldman Sachs Optimistic About Nvidia's Growth Prospects
- Strategic Partnerships Drive Growth: Goldman Sachs highlights that Nvidia's strategic partnerships with biotech firms are emerging as a major catalyst, enabling the company to test and refine its AI models in lab settings, thereby enhancing its application potential in healthcare and life sciences.
- Significant Investment Returns: Nvidia's investment in Recursion Pharmaceuticals showcases the potential of AI in drug discovery, as Recursion's technology platform dramatically shortens the timeline for human testing, indicating that AI-driven efficiencies are yielding tangible benefits for the company.
- Strong Market Demand: Goldman Sachs reiterated its 'Buy' rating on Nvidia with a price target of $250, implying a 51% upside from Monday's closing price, reflecting ongoing expectations for growing demand for AI-driven computing across specialized industries.
- Stock Volatility and Sentiment: Despite Nvidia's stock trading over 3% higher on Tuesday morning, retail sentiment on Stocktwits remains bearish, indicating low engagement and concern among retail investors regarding the stock's performance.
See More
US Stocks Surge as Market Sentiment Improves
- Market Sentiment Improves: The S&P 500 index rose by 1.02%, the Dow Jones Industrial Average increased by 0.67%, and the Nasdaq 100 surged by 1.10% as President Trump signaled a willingness to end military actions against Iran, reflecting investor optimism over easing geopolitical risks.
- Falling Bond Yields: The 10-year Treasury note yield dropped to a one-week low of 4.30%, indicating market expectations that an end to the Iran conflict could lower energy prices and alleviate inflation concerns, further supporting stock market gains.
- Consumer Confidence Rises: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing expectations of a decline to 87.9, suggesting enhanced consumer confidence in economic prospects, which could drive spending and economic growth.
- Strong Chinese Economy: China's March manufacturing PMI rose to 50.4, exceeding expectations of 50.1, indicating signs of economic recovery that support global growth prospects and positively influence market performance.
See More
Snap Shares Surge on Activist Investor Proposal
- Snap Share Surge: Shares of social media platform Snap surged 12% after activist investor Irenic disclosed a 2.5% stake and proposed shutting down its augmented reality Specs business to boost share prices, indicating strong market confidence in its strategic direction.
- FactSet Earnings Beat: FactSet's adjusted earnings for Q2 came in at $4.46 per share, exceeding the consensus estimate of $4.38, while the company raised its full-year guidance to an expected adjusted earnings range of $17.25 to $17.75 per share, reflecting robust market performance and growth potential.
- Symbotic Strategic Agreement: Robotics company Symbotic's stock jumped nearly 5% following a strategic agreement to provide warehouse automation capabilities at Associated Wholesale Grocers' Gulf Coast Division Support Center in Louisiana, highlighting its expansion in logistics automation and growing market demand.
- Apellis Pharmaceuticals Stock Doubles: Shares of Apellis Pharmaceuticals soared 135% after Biogen announced it would acquire the company for $5.6 billion in cash, enhancing Biogen's portfolio in immunology and rare diseases, showcasing strong market approval for the deal.
See More
Nvidia Reports 65% Revenue Growth in Fiscal 2026
- Significant Revenue Growth: Nvidia reported a revenue of $215.9 billion for fiscal 2026, reflecting a 65% year-over-year increase, despite a 10.2% decline in stock price so far in 2026, indicating market concerns about the sustainability of AI infrastructure spending.
- Robust AI Demand Outlook: CEO Jensen Huang announced at the GTC AI Conference that demand for AI systems is projected to reach at least $1 trillion in 2026 and 2027, a substantial increase from the previous estimate of $500 billion, highlighting the long-term trend in AI infrastructure development.
- Diversified Customer Base: Nvidia's business is composed of 60% from hyperscalers and 40% from enterprises, sovereign AI projects, startups, and emerging applications, ensuring that the company is not overly reliant on any single industry, thereby mitigating market risks.
- Continuous Product Innovation: Nvidia is actively launching new products, with ongoing deployments of Hopper systems and ramping up Blackwell systems, while future platforms like Rubin and Feynman are already in development, enhancing the company's competitive edge in the market.
See More
Harbor Capital's Strategic Buy and Sell Moves in Q1 2026
- New Stock Additions: In Q1 2026, Harbor Capital added three stocks, with Merck & Co (MRK) being the largest at 2,020,767 shares, accounting for 0.86% of the portfolio and valued at $222.83 million, indicating confidence in the pharmaceutical sector.
- Key Position Increases: The fund increased its stake in Amphenol Corp (APH) by 818,193 shares, representing a significant 58.39% increase, bringing total holdings to 2,219,459 shares with an overall investment value of $319.78 million, reflecting optimism about its growth potential.
- Complete Exits: Harbor Capital fully exited four holdings in Q1, including Nike (NKE) and Boston Scientific (BSX), impacting the portfolio by -0.74% and -0.45% respectively, indicating a cautious outlook on these companies.
- Position Reductions: The fund reduced stakes in 34 stocks, notably cutting NVIDIA (NVDA) by 3,792,310 shares, resulting in a 20.42% decrease and a -2.61% portfolio impact, showcasing a strategic response to market volatility.
See More
Nvidia Invests Over $18B to Propel AI Ecosystem
- Total Strategic Investments: Nvidia has invested at least $18 billion in publicly traded companies over the past six months, underscoring its ongoing expansion and dominance in the AI sector.
- Partnership with Marvell: The latest $2 billion investment in Marvell Technology aims to connect Marvell to Nvidia's AI factory and AI-RAN ecosystem through NVLink Fusion, further solidifying their strategic partnership.
- Diverse Investment Strategy: Earlier this month, Nvidia invested $2 billion in Dutch AI infrastructure provider Nebius, planning to deploy over 5 gigawatts of Nvidia systems by the end of 2030, showcasing its ambition in global AI infrastructure development.
- Historic Collaboration with Intel: Nvidia's $5 billion share purchase from Intel at the end of 2025 aims to tightly integrate Nvidia's AI computing platform with Intel's CPUs, laying the groundwork for the next era of computing.
See More
Goldman Sachs Optimistic About Nvidia's Growth Prospects
- Strategic Partnerships Drive Growth: Goldman Sachs highlights that Nvidia's strategic partnerships with biotech firms are emerging as a major catalyst, enabling the company to test and refine its AI models in lab settings, thereby enhancing its application potential in healthcare and life sciences.
- Significant Investment Returns: Nvidia's investment in Recursion Pharmaceuticals showcases the potential of AI in drug discovery, as Recursion's technology platform dramatically shortens the timeline for human testing, indicating that AI-driven efficiencies are yielding tangible benefits for the company.
- Strong Market Demand: Goldman Sachs reiterated its 'Buy' rating on Nvidia with a price target of $250, implying a 51% upside from Monday's closing price, reflecting ongoing expectations for growing demand for AI-driven computing across specialized industries.
- Stock Volatility and Sentiment: Despite Nvidia's stock trading over 3% higher on Tuesday morning, retail sentiment on Stocktwits remains bearish, indicating low engagement and concern among retail investors regarding the stock's performance.
See More
US Stocks Surge as Market Sentiment Improves
- Market Sentiment Improves: The S&P 500 index rose by 1.02%, the Dow Jones Industrial Average increased by 0.67%, and the Nasdaq 100 surged by 1.10% as President Trump signaled a willingness to end military actions against Iran, reflecting investor optimism over easing geopolitical risks.
- Falling Bond Yields: The 10-year Treasury note yield dropped to a one-week low of 4.30%, indicating market expectations that an end to the Iran conflict could lower energy prices and alleviate inflation concerns, further supporting stock market gains.
- Consumer Confidence Rises: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing expectations of a decline to 87.9, suggesting enhanced consumer confidence in economic prospects, which could drive spending and economic growth.
- Strong Chinese Economy: China's March manufacturing PMI rose to 50.4, exceeding expectations of 50.1, indicating signs of economic recovery that support global growth prospects and positively influence market performance.
See More
Snap Shares Surge on Activist Investor Proposal
- Snap Share Surge: Shares of social media platform Snap surged 12% after activist investor Irenic disclosed a 2.5% stake and proposed shutting down its augmented reality Specs business to boost share prices, indicating strong market confidence in its strategic direction.
- FactSet Earnings Beat: FactSet's adjusted earnings for Q2 came in at $4.46 per share, exceeding the consensus estimate of $4.38, while the company raised its full-year guidance to an expected adjusted earnings range of $17.25 to $17.75 per share, reflecting robust market performance and growth potential.
- Symbotic Strategic Agreement: Robotics company Symbotic's stock jumped nearly 5% following a strategic agreement to provide warehouse automation capabilities at Associated Wholesale Grocers' Gulf Coast Division Support Center in Louisiana, highlighting its expansion in logistics automation and growing market demand.
- Apellis Pharmaceuticals Stock Doubles: Shares of Apellis Pharmaceuticals soared 135% after Biogen announced it would acquire the company for $5.6 billion in cash, enhancing Biogen's portfolio in immunology and rare diseases, showcasing strong market approval for the deal.
See More
